Top MarketRank™ StocksTop MarketRank™NASDAQ:AMPH Amphastar Pharmaceuticals (AMPH) Stock Price, News & Analysis $45.38 -0.04 (-0.09%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$45.17▼$46.0350-Day Range$36.99▼$48.8652-Week Range$36.56▼$65.92Volume239,076 shsAverage Volume409,593 shsMarket Capitalization$2.22 billionP/E Ratio15.70Dividend YieldN/APrice Target$63.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Amphastar Pharmaceuticals alerts: Email Address Amphastar Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside38.8% Upside$63.00 Price TargetShort InterestBearish12.02% of Float Sold ShortDividend StrengthN/ASustainability-2.21Upright™ Environmental ScoreNews Sentiment1.03Based on 11 Articles This WeekInsider TradingSelling Shares$1.80 M Sold Last QuarterProj. Earnings Growth14.29%From $3.71 to $4.24 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.91 out of 5 starsMedical Sector14th out of 910 stocksPharmaceutical Preparations Industry5th out of 426 stocks 3.3 Analyst's Opinion Consensus RatingAmphastar Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAmphastar Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Amphastar Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.02% of the float of Amphastar Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmphastar Pharmaceuticals has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in Amphastar Pharmaceuticals has recently decreased by 7.47%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmphastar Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmphastar Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmphastar Pharmaceuticals has received a 46.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Subcutaneous human immunoglobulin", "Procainamide", "Epinephrine", and "Medroxyprogesterone acetate" products. See details.Environmental SustainabilityThe Environmental Impact score for Amphastar Pharmaceuticals is -2.21. Previous Next 3.3 News and Social Media Coverage News SentimentAmphastar Pharmaceuticals has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Amphastar Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for AMPH on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows4 people have added Amphastar Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,795,507.00 in company stock.Percentage Held by Insiders27.10% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.09% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amphastar Pharmaceuticals' insider trading history. Previous Next 3.8 Earnings and Valuation Earnings GrowthEarnings for Amphastar Pharmaceuticals are expected to grow by 14.29% in the coming year, from $3.71 to $4.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amphastar Pharmaceuticals is 15.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Amphastar Pharmaceuticals is 15.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.06.Price to Earnings Growth RatioAmphastar Pharmaceuticals has a PEG Ratio of 0.92. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAmphastar Pharmaceuticals has a P/B Ratio of 3.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amphastar Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH)Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Read More AMPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMPH Stock News HeadlinesSeptember 7 at 9:07 AM | insidertrades.comInsider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells 3,000 Shares of StockAugust 30, 2024 | insidertrades.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou Sells 4,000 SharesSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 14, 2024 | insidertrades.comInsider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells 17,101 Shares of StockSeptember 7 at 6:14 AM | finance.yahoo.comInsider Sale: Director Floyd Petersen Sells Shares of Amphastar Pharmaceuticals Inc (AMPH)September 3, 2024 | americanbankingnews.comAmphastar Pharmaceuticals (NASDAQ:AMPH) Rating Increased to Buy at StockNews.comAugust 29, 2024 | seekingalpha.comThe Broad Market Has Not Participated In This RallyAugust 28, 2024 | finanznachrichten.deAmphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare ConferenceSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 28, 2024 | americanbankingnews.comAmphastar Pharmaceuticals (NASDAQ:AMPH) Downgraded to Hold at StockNews.comAugust 28, 2024 | americanbankingnews.comAmphastar Pharmaceuticals (NASDAQ:AMPH) Cut to "Hold" at StockNews.comAugust 17, 2024 | markets.businessinsider.comAmphastar Pharmaceuticals Poised for Growth: Strong Product Performance and Strategic Financial Health Drive Buy RatingAugust 9, 2024 | seekingalpha.comAmphastar Pharmaceuticals, Inc. (AMPH) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | finance.yahoo.comAmphastar Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsAugust 9, 2024 | seekingalpha.comAmphastar Pharmaceuticals, Inc. 2024 Q2 - Results - Earnings Call PresentationAugust 8, 2024 | markets.businessinsider.comAmphastar Pharmaceuticals Upholds Buy Rating Amid Strong Q2 Earnings and Promising Growth OutlookAugust 8, 2024 | markets.businessinsider.comAmphastar Pharmaceuticals Hold Rating Affirmed Amid Competitive Pressures and Pipeline ChallengesAugust 8, 2024 | markets.businessinsider.comHere's what Wall Street expects from Amphastar Pharmaceuticals's earnings reportSee More Headlines Receive AMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AMPH CUSIPN/A CIK1297184 Webwww.amphastar.com Phone(909) 980-9484Fax909-980-8296Employees1,761Year FoundedN/APrice Target and Rating Average Stock Price Target$63.00 High Stock Price Target$66.00 Low Stock Price Target$60.00 Potential Upside/Downside+38.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$2.89 Trailing P/E Ratio15.70 Forward P/E Ratio12.23 P/E Growth0.92Net Income$137.54 million Net Margins23.36% Pretax Margin28.49% Return on Equity29.79% Return on Assets12.75% Debt Debt-to-Equity Ratio0.82 Current Ratio3.52 Quick Ratio2.63 Sales & Book Value Annual Sales$712.89 million Price / Sales3.11 Cash Flow$4.07 per share Price / Cash Flow11.16 Book Value$14.65 per share Price / Book3.10Miscellaneous Outstanding Shares48,902,000Free Float35,650,000Market Cap$2.22 billion OptionableOptionable Beta0.79 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Ziping Luo Ph.D. (Age 74)Chairman of the Board, Chief Scientist & COO Comp: $1.53MDr. Yongfeng Zhang Ph.D. (Age 77)Co-Founder, President, CEO, Chief Scientific Officer & Director Comp: $2.13MMr. William J. Peters M.B.A. (Age 56)CFO, Executive VP of Finance, Treasurer & Director Comp: $1.12MMr. Jacob Liawatidewi M.B.A. (Age 50)Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director Comp: $794.15kMr. Rong Zhou M.S. (Age 65)Senior Executive Vice President of Production Comp: $835.05kDan Dischner M.B.A.Vice President of Human Resources & Corporate CommunicationTony Marrs M.B.A.M.P.H., Senior VP of Regulatory Affairs & Clinical OperationsMore ExecutivesKey CompetitorsProtagonist TherapeuticsNASDAQ:PTGXFive Prime TherapeuticsNASDAQ:FPRXSyndax PharmaceuticalsNASDAQ:SNDXCalliditas Therapeutics AB (publ)NASDAQ:CALTPhibro Animal HealthNASDAQ:PAHCView All CompetitorsInsiders & InstitutionsCim LLCBought 701 shares on 9/6/2024Ownership: 0.020%Floyd F PetersenSold 3,000 sharesTotal: $139,410.00 ($46.47/share)Sanctuary Advisors LLCBought 9,439 shares on 9/5/2024Ownership: 0.019%Rong ZhouSold 4,000 sharesTotal: $193,400.00 ($48.35/share)Aurora Investment CounselBought 54,466 shares on 8/22/2024Ownership: 0.111%View All Insider TransactionsView All Institutional Transactions AMPH Stock Analysis - Frequently Asked Questions How have AMPH shares performed this year? Amphastar Pharmaceuticals' stock was trading at $61.85 on January 1st, 2024. Since then, AMPH shares have decreased by 26.6% and is now trading at $45.38. View the best growth stocks for 2024 here. How were Amphastar Pharmaceuticals' earnings last quarter? Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced its quarterly earnings data on Wednesday, August, 7th. The company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.10. The company earned $182.39 million during the quarter, compared to analyst estimates of $171.29 million. Amphastar Pharmaceuticals had a net margin of 23.36% and a trailing twelve-month return on equity of 29.79%. What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO? 35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend. Who are Amphastar Pharmaceuticals' major shareholders? Top institutional investors of Amphastar Pharmaceuticals include Federated Hermes Inc. (3.98%), TD Asset Management Inc (3.46%), Epoch Investment Partners Inc. (2.21%) and Dimensional Fund Advisors LP (2.19%). Insiders that own company stock include Jack Y Zhang, Mary Z Luo, Howard Lee, Rong Zhou, William J Peters, Floyd F Petersen, Yakob Liawatidewi, Richard K Prins, Michael A Zasloff and Diane G Gerst. View institutional ownership trends. How do I buy shares of Amphastar Pharmaceuticals? Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Amphastar Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU) and AbbVie (ABBV). This page (NASDAQ:AMPH) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amphastar Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
